ClinicalTrials.gg
RecruitingNCT07499765ANX-LAUpdated Apr 29, 2026

Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis

An interventional study of care support program after diagnosis announcement in Acute Leukemia, sponsored by Centre Henri Becquerel. Recruiting at 1 site in France. Open to participants aged 26 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
26 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to determine the impact on anxiety between patients with a period of care support following their announcement of an acute leukemia (AL) diagnosis and patients without this accompaniment.

Read the detailed description

Patients answering the inclusion and exclusion criteria will be offered the opportunity to participate in the study by a nurse trained in this method of period of care support at the time of their announcement of an AL diagnosis. Patients will be given sufficient time to consider their decision. Following this period, patients who wish to participate will be included in the study, will sign the informed consent form and will be randomized (with or without a period of care support following their announcement of an AL diagnosis).

Patients in both groups will have their anxiety and quality of life questionnaire (QLQ-C30) assessed within the context of their usual care at T0 (at the time of the announcement).

Patients randomized in the arm with period of care support meet the nurse for this accompaniment within 7 days after the announcement.

Patients in both groups will have their anxiety at T1 (within 24 hours after the period of care support for the experimental group, same timeframe for the control group), and again their anxiety and quality of life at T2, two months (± 3 days) after admission to the intensive care unit. An evaluation questionnaire concerning period of care support will be given to the group benefiting from this care and a satisfaction questionnaire for the care will be given to patients in both groups at T2.

02

Conditions studied

  • Acute Leukemia

Browse trials for

Keywords

  • acute leukemia
  • anxiety
  • care support program
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 110 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Centre Henri Becquerel is the lead sponsor of 59 studies on the registry; 17 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
26 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed
  • medical confirmation of acute leukemia diagnosis
  • age equal of superior to 26 years and under 80 years
  • confirmed diagnosis not yet treated
  • hospitalization at Centre Henri Becquerel
  • member or beneficiary of a social security

Exclusion criteria

Exclusion Criteria:

  • -Patient unable to understand the study for any reason or to comply with the trial's requirements
  • Patient in relapse of acute leukemia
  • Patient diagnosed with acute myeloid leukemia 3
  • History of cancer within the 5 years preceding the year of study enrollment
  • Alcohol and drug abuse
  • Inclusion in another therapeutic trial that prevents further enrollment in a trial evaluating quality of life or psychological well-being
  • Diagnosed psychiatric illness
  • Patient under guardianship, curatorship, or legal protection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • No intervention
    Standard arm

    After randomization and diagnosis announcement, patient will be followed as usually

  • Experimental
    Experimental arm

    After randomization and diagnosis announcement, patient will have dedicated time with a nurse to explain in detail the diagnosis, the treatment. The anxiety will be also evaluated at different timepoints

    Other: care support program after diagnosis announcement

Interventions

  • Othercare support program after diagnosis announcement

    a dedicated time with a specialized nurse in announcement will be given tot the patient. The anxiety will also be evaluated

06

What researchers measure

Primary outcomes

  1. Anxiety improvment

    variation of anxiety level using STAI questionnaire

    Time frame: 7 days after diagnosis announcement

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2029, 36 months later.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 36 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Mar 30, 2026
Primary completionEst.
Mar 30, 2029
CompletionEst.
Apr 15, 2029
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07499765
Lead sponsor
Centre Henri Becquerel
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 30, 2026 (estimated)
Primary completion
Mar 30, 2029 (estimated)
Completion
Apr 15, 2029 (estimated)
Last update
Apr 29, 2026

Study contacts

Johan Le Fel, PhD
Contact
johan.lefel@chb.unicancer.fr
+232082918
Doriane Richard, PhD
Contact
doriane.richard@chb.unicancer.fr
+33232082985
Fabrice Jardin, Md PhD
principal investigator · Centre Henri Becquerel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion